J Korean Orthop Assoc.  2015 Dec;50(6):438-443. 10.4055/jkoa.2015.50.6.438.

Current Strategy of Chemotherapy for Bone Tumors

• Kim HS
• Rha SY

• KMID: 2185084
• DOI: http://doi.org/10.4055/jkoa.2015.50.6.438

Abstract

Despite the rarity of primary bone tumors, osteosarcoma and Ewing sarcoma are the most common primary malignant bone tumors in children and adolescents. Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment remarkably improved the survival outcome for patients with osteosarcoma and Ewing sarcoma, therefore, most patients are now limb-salvage candidates. However, survival rate reached a plateau for last decades and is still unsatisfactory in the metastatic and relapse setting. Therefore, as seen in denosumab in giant cell tumor, further clinical trials based on molecular mechanism are warranted. This article reviews the current state of the art of systemic chemotherapy by focusing on the clinical heterogeneity of each subtype.

Keyword

bone tumor; chemotherapy

MeSH Terms

Adolescent
Child
Drug Therapy*
Giant Cell Tumors
Humans
Osteosarcoma
Population Characteristics
Recurrence
Sarcoma, Ewing
Survival Rate
Denosumab

Reference

1. Hogendoorn PC, Athanasou N, Bielack S, et al. ESMO/EUROBONET Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21:Suppl 5. v204–v213.

2. Fletcher CDM, Hogendoorm P, Mertens F. WHO classification of tumours of soft tissue and bone. Lyon: IARC Press;2013. 5.

3. Schajowicz F, McGuire MH, Santini Araujo E, Muscolo DL, Gitelis S. Osteosarcomas arising on the surfaces of long bones. J Bone Joint Surg Am. 1988; 70:555–564.

4. Grimer RJ, Bielack S, Flege S, et al. European Musculo Skeletal Oncology Society. Periosteal osteosarcoma: a European review of outcome. Eur J Cancer. 2005; 41:2806–2811.

5. Cesari M, Alberghini M, Vanel D, et al. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011; 117:1731–1735.

6. Bernthal NM, Federman N, Eilber FR, et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012; 118:5888–5893.

7. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992; 10:1579–1591.

8. Lewis IJ, Nooij MA, Whelan J, et al. MRC BO06 and EORTC 80931 collaborators. European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007; 99:112–128.

9. Smeland S, Müller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003; 39:488–494.

10. Smeland S, Bruland OS, Hjorth L, et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years. Acta Orthop. 2011; 82:211–216.

11. Le Deley MC, Guinebretière JM, Gentet JC, et al. Société Française d'Oncologie Pédiatrique (SFOP). SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007; 43:752–761.

12. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997; 15:76–84.

13. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer. 2005; 41:2079–2085.

14. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer. 1997; 33:232–237.

15. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008; 113:419–425.

16. Saylors RL 3rd, Stine KC, Sullivan J, et al. Pediatric Oncology Group. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001; 19:3463–3469.

17. Van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Pediatr Blood Cancer. 2005; 44:338–347.

18. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012; 23:508–516.

19. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005; 23:2004–2011.

20. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004; 100:2222–2232.

21. Nagarajan R, Kamruzzaman A, Ness KK, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 2011; 117:625–634.

22. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003; 348:694–701.

23. Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am. 2004; 86:2412–2418.

24. Dantonello TM, Int-Veen C, Leuschner I, et al. CWS study group. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008; 112:2424–2431.

25. Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S, et al. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007; 93:423–427.

26. Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res. 2010; 468:827–833.

27. Roux S, Mariette X. RANK and RANKL expression in giant-cell tumour of bone. Lancet Oncol. 2010; 11:514.

28. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010; 11:275–280.

29. Branstetter DG, Nelson SD, Manivel JC, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012; 18:4415–4424.

30. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013; 14:901–908.